

ENSAYOS CLÍNICOS FASE I

- TUMORES SÓLIDOS

AMGEN 20140318

"A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors"

<https://clinicaltrials.gov/ct2/show/NCT02509507?term=20140318&rank=1>

CLGK974X2101

"Estudio fase I, abierto, de escalada de dosis de LGK974 oral, en pacientes con enfermedades malignas dependientes de ligandos de Wnt".

<https://clinicaltrials.gov/ct2/show/NCT01351103?term=CLGK974X2101&rank=1>

CNZV930X2101

"Estudio de fase I/Ib, multicéntrico y abierto de NZV930 en monoterapia y en combinación con PDR001 y/o NIR178 en pacientes con tumores malignos avanzados"

<https://clinicaltrials.gov/ct2/show/NCT03549000?term=CNZV930X2101&recrs=a&phase=0&rank=1>

IOV-COM-202

"A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors"

<https://clinicaltrials.gov/ct2/show/NCT03645928?term=IOV-COM-202&rank=1>

CVPM087A2101

"Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapy in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma".

<https://clinicaltrials.gov/ct2/show/NCT03798626?term=CVPM&rank=1>

M16-074

"A Multicenter, phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics of ABBV-368 as a single agent and combination in subjects with locally advanced or metastatic solid tumors".

<https://clinicaltrials.gov/ct2/show/NCT03071757>

MK7339-007

*"A Phase 2 Study of Pembrolizumab in Combination with Olaparib in Participants with Previously Treated, **Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer**"*

<https://clinicaltrials.gov/ct2/show/NCT04123366?term=MK7339-007&draw=2&rank=1>

ARRAY 818-103

"Estudio de fase 1, abierto para evaluar las interacciones farmacológicas de los fármacos administrados junto con encorafenib y binimetinib en pacientes con melanoma irresecable o metastásico o con otros tumores sólidos avanzados con mutación de BRAF V600"

<https://clinicaltrials.gov/ct2/results?term=ARRAY+818-103&Search=Search>

MK-7902-005-00

"A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)"

<https://clinicaltrials.gov/ct2/show/NCT03797326?term=MK-7902-005&rank=1>

DS8201-A-U106

A Phase 1b, multicenter, two-part, open-label study of trastuzumab deruxtecan, an anti-human epidermal growth factor receptor-2 (HER2)-antibody drug conjugate (ADC), in combination with pembrolizumab, an anti-PD-1 antibody, in subjects with locally advanced/metastatic breast or non-small cell lung cancer (NSCLC)

<https://clinicaltrials.gov/ct2/show/NCT04042701>

LOX-TRK-15002 (BAY2757556/20289)

*"Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors. (**Melanoma, Pulmón, Mama no secretor y Colorectal**)"*

<https://clinicaltrials.gov/ct2/show/NCT02576431>

CA022-001

"Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors"

<https://clinicaltrials.gov/ct2/show/NCT03110107?term=CA022-001&draw=2&rank=1>

AMGEN 2019-0131

"A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors"

<https://clinicaltrials.gov/ct2/show/NCT04293094>

- SARCOMAS

TRASTS

“Ensayo Clínico Fase I-II abierto, prospectivo y multicéntrico, que explora la combinación de trabectedina y radioterapia en pacientes con sarcoma de tejidos blandos”

<https://clinicaltrials.gov/ct2/show/NCT02275286?term=TRASTS&rank=1>

- PULMON

61186372EDI1001

“A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer”

<https://clinicaltrials.gov/ct2/show/NCT02609776?term=61186372EDI1001&rank=1>

LUPER

“Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer (the LUPER study)”

<https://clinicaltrials.gov/ct2/show/NCT04358237?term=LUPER&draw=2&rank=1>

73841937NSC1001

“Estudio Fase I/Ib abierto para evaluar la seguridad y farmacocinética de JNJ-73841937 (lazertinib), un inhibidor de la tirosinaquinasa del EGFR (TKI-EGFR) de tercera generación, en monoterapia o en combinación con JNJ-61186372, un anticuerpo humano biespecífico frente a EGFR y cMet, en pacientes con cáncer de pulmón no microcítico avanzado”

<https://clinicaltrials.gov/ct2/show/NCT04077463>

-COLORRECTAL

CADPT01C12101

“Estudio plataforma de fase Ib, multicéntrico, abierto y con escalada y expansión de dosis de combinaciones seleccionadas de fármacos en pacientes adultos con cáncer colorrectal avanzado o metastásico con mutación V600 de BRAF”

<https://clinicaltrials.gov/ct2/show/NCT04294160>

-MAMA

MEN1611- PRECISE

"Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a/m) Breast Cancer Progressed to Anti-HER2 Based Therapy"

<https://clinicaltrials.gov/ct2/show/NCT03767335?term=MEN1611&rank=1>

J2J-MC-JZLB

"EMBER-2: A Phase 1, Open-Label, Preoperative Window Study evaluating the Biological Effects of LY3484356 in Post-menopausal Women with Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer"

<https://clinicaltrials.gov/ct2/show/NCT04647487>

- GÁSTRICO

DESTINY-GASTRIC03

"A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (DS-8201a) Monotherapy and combinations in Adult Participants with HER-2 Overexpressing Gastric Cancer"

<https://clinicaltrials.gov/ct2/show/NCT04379596>

- PÁNCREAS

WO39608

"Estudio en paraguas de fase Ib/II, sin enmascaramiento, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de combinaciones de tratamientos basados en múltiples inmunoterapias en pacientes con adenocarcinoma ductal pancreático metastásico (morpheus-cáncer pancreático)"

<https://clinicaltrials.gov/ct2/show/NCT03193190?term=WO39608&rank=1>

- UROTELIO/VEJIGA

WO39613

"ESTUDIO EN PARAGUAS DE FASE IB / II, ABIERTO, MULTICÉNTRICO, ALEATORIZADO, QUE EVALÚA LA EFICACIA Y LA SEGURIDAD DE LAS COMBINACIONES DE TRATAMIENTOS BASADOS EN MÚLTIPLES INMUNOTERAPIAS EN PACIENTES CON CARCINOMA UROTELIAL LOCALMENTE AVANZADO O METASTÁSICO TRAS FRACASO DE TRATAMIENTO CON QUIMIOTERAPIA CON PLATINO (MORPHEUS-Muc)"

<https://clinicaltrials.gov/ct2/show/NCT03869190?term=WO39613&rank=1>